ASCO 2023 | Feasibility of the IPSS-M in CMML
Luis Aguirre, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of a study evaluating the applicability of the IPSS-Molecular (IPSS-M) prognostic scoring system developed for myelodysplastic syndromes (MDS) in chronic myelomonocytic leukemia (CMML). Overall, it was found that the prognostic accuracy of the IPSS-M was similar to that of other scoring systems developed specifically for CMML. These findings suggest that the IPSS-M can reliably be used to risk stratify patients and guide treatment decisions in CMML, particularly in community settings where misdiagnosis with MDS is common. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
